Tissue Eosinophilia in Relation to Immunopathological and Clinical Characteristics in Hodgkin's Disease

References

• Vaughan Hudson B., Linch D., Macintyre E., Bennett M., MacLennan K., Vaughan Hudson G., Jelliffe A. Selective peripheral blood eosinophilia associated with survival advantage in Hodgkin's disease (BNLI Report No 31). Journal of Clinical Pathology 1987; 40: 247–250
   PubMed Web of Science ®Google Scholar
• Samoszuk M., Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990; 75: 13–16
   PubMed Web of Science ®Google Scholar
• Desenne J., Acquatella G., Stern R., Muller A., Sanchez M., Somoza R. Blood eosinophilia in Hodgkin's disease. A follow-up of 25 cases in Venezuela. Cancer 1992; 69: 1248–1253
   PubMed Web of Science ®Google Scholar
• Enblad G., Sundström C., Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematological Oncology 1993; 11: 187–193
   PubMed Web of Science ®Google Scholar
• von Wasielewski R., Seth S., Franklin J., Fischer R., Hubner K., Hansmann M. L., Diehl V., Georgü A. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 2000; 95: 1207–1213
   PubMed Web of Science ®Google Scholar
• Rothenburg M. Eosinophilia. New England Journal of Medicine 1998; 338: 1592–1600
   PubMed Web of Science ®Google Scholar
• Jundt F., Anagnostopoulos I., Bommert K., Emmerich F., Muller G., Foss H. D., Royer H. D., Stein H., Dorken B. Hodgkin/Reed-Stemberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999; 94: 2065–2071
   PubMed Web of Science ®Google Scholar
• Poppema S., Potters M., Emmens R., Visser L., van den Berg A. Immune reactions in classical Hodgkin's lymphoma. Seminars in Hematology 1999; 36: 253–259
   PubMed Web of Science ®Google Scholar
• Ben-Ezra J., Sheibani K., Swartz W., Stroup R., Traweek T., Kezirian J., Rappaport H. Relationship between eosinophil density and T-cell activation markers in lymph nodes of patients with Hodgkin's Disease. Human Pathology 1989; 20: 1181–1185
   PubMed Web of Science ®Google Scholar
• Levi-Schaffer F., Garbuzenko E., Rubin A., Reich R., Pickholz D., Gillery P., Emonard H., Nagler A., Maquart F A. Human eosinophils regulate human lung-and skin-derived fibroblast properties in vitro: A role for transforming growth factor beta (TGF-β). Proceeding of the National Academy of Sciences of the United States of America. 1999. 96: 9660–9665
   Google Scholar
• Kadin M., Agnarsson B., Ellingsworth R., Newcom S. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. American Journal of Pathology 1990; 136: 1209–1214
   PubMed Web of Science ®Google Scholar
• Kadin M., Butmarc J., Elovic A., Wong D. Eosinophils are the major source of transforming growth factor-β 1 in nodular sclerosing Hodgkin's disease. American Journal of Pathology 1993; 142: 11–16
   PubMed Web of Science ®Google Scholar
• Newcom S., Gu L. Transforming growth factor (β1) messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. Journal of Clinical Pathology 1995; 48: 160–163
   PubMed Web of Science ®Google Scholar
• Kehrl J. Transforming growth factor-β, an important mediator of immunoregulation. International Journal of Cell Cloning 1991; 9: 438–450
   PubMedGoogle Scholar
• Wedelin C., Björkholm M., Holm G., Ogenstad S., Johansson B., Mellstedt H. Lymphocyte function in untreated Hodgkin's disease: An important predictor of prognosis. British Journal of Cancer 1982; 45: 70–79
   PubMed Web of Science ®Google Scholar
• Pinto A., Aldinucci D., Gloghini A., Zagonel V., Degan M., Perin V., Todesco M., de Iuliis A., Irnprota S., Sacco C., Gattei V., Gruss H. J., Carbone A. The role of eosinophils in the pathobiology of Hodgkin's disease. Annals of Oncology 1997; 8: 89–96
   PubMed Web of Science ®Google Scholar
• Colby T., Hoppe R., Wamke R. Hodgkin's disease, a clinicopathologic study of 659 cases. Cancer 1982; 49: 1848–1858
   PubMed Web of Science ®Google Scholar
• d'Amore E., Lee C., Aeppli D., Levitt S., Frizzera G. Lack of prognostic value of histopathologic parameters in Hodgkin's disease, nodular sclerosis type. Archives of pathology and laboratory medicine 1992; 116: 856–861
   PubMedGoogle Scholar
• Mir R., Anderson J., Strauchen J., Nissen N., Cooper M., Rafla S., Canellos G., Bloomfield C., Gottlieb A., Peterson B., Barcos M., The Cancer and Leukemia Group B. Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. Cancer 1993; 71: 1857–1866
   PubMed Web of Science ®Google Scholar
• Hess J., Bodis S., Pinkus G., Silver B., Mauch P. Histopathologic grading of nodular sclerosis Hodgkin's disease. Cancer 1994; 74: 708–714
   PubMed Web of Science ®Google Scholar
• Axdorph U., Porwit-MacDonald A., Sjöberg J., Grimfors G., Ekman M., Wang W., Biberfeld P., Björkholm M. Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function. British Journal of Cancer 1999; 81: 1182–1187
   PubMed Web of Science ®Google Scholar
• Carbone P., Kaplan H., Musshoff K., Smithers D., Tubiana M. Report of the Committee on Hodgkin's disease staging classification. Cancer Research 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Björkholm M., Holm G., Mellstedt H., Johansson B., Killander D., Sundblad R., Söderberg G. Prognostic factors in Hodgkin's disease. II. The role of lymphocyte defect. Scandinavian Journal of Haematolology 1978; 20: 306–308
   PubMedGoogle Scholar
• Björkholm M., Axdorph U., Grimfors G., Merk K., Johansson B., Svedmyr E., Mellstedt H., Holm G. Fixed versus response adapted MOPP/ABVD chemotherapy in Hodgkin's disease. Annals of Oncology 1995; 6: 895–899
   PubMed Web of Science ®Google Scholar
• Askergren J., Björkhohn M., Holm G., Johansson B., Mellstedt H. Prognostic influence of early diagnostic splenectomy in Hodgkin's disease. A long-term follow-up. Acta Medica Scandinavia 1986; 219: 315–322
   PubMed Web of Science ®Google Scholar
• Grimfors G., Andersson B., Tullgren O., Giscombe R., Holm G., Johansson B., Björkhohn M. Increased serum CD 8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of poor prognosis in adult Hodgkin's disease. British Journal of Haematology 1992; 80: 166–171
   PubMed Web of Science ®Google Scholar
• Harris N., Jaffe E., Stein H., Banks P., Chan J., Cleary M., Delsol G., de Wolf-Peeters C., Falini B., Gatter K., Grogan T., Isaacson P., Knowles D., Mason D., Muller-Hermelink H. K., Pileri S., Pins M., Ralfkiaer E., Wamke R. A revised European-American classification of lymphoid neoplasms. A proposal from the international lymphoma study group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• MacLennan K., Bennett M., Tu A., Vaughan Hudson B., Easterling J., Vaughan Hudson G., Jelliffe A. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. Cancer 1989; 64: 1686–1693
   PubMed Web of Science ®Google Scholar
• Altman D. G. Inter-rater Agreement. Practical Statistics for Medical Research. Chapman and Hall, London 1991; 403–409
   Google Scholar
• Specht L., Lauritzen A. F., Nordentoft A., Andersen P., Christensen B., Hippe E., Hou-Jensen K., Nissen N., Danish National Hodgkin Study Group. Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. Cancer 1990; 65: 2594–2601
   PubMed Web of Science ®Google Scholar
• Czader M., Porwit A., Tani E., Öst A., Mazur J., Auer G. DNA image cytometry and the expression of proliferative markers (proliferating cell nuclear antigen and Ki67) in non-Hodgkin's lymphomas. Modern Patholology 1995; 8: 51–58
   PubMed Web of Science ®Google Scholar
• Holm G., Mellstedt H., Björkhohn M., Johansson B., Killander D., Sundblad R., Söderberg G. Lymphocyte abnormalities in untreated patients with Hodgkin's disease. Cancer 1976; 37: 751–762
   PubMed Web of Science ®Google Scholar
• Armitage P., Berry G. Statistical methods in medical research. third edn. Blackwell Publication, Cambridge 1994; 137–141
   Google Scholar
• Mehta C., Patel N., Tsiatis A. Exact significance testing to establish treatment equivalence for ordered categorial data. Biometrics 1984; 40: 819–825
   PubMed Web of Science ®Google Scholar
• Armitage P., Berry G. Statistical methods in medical research. third edn. Blackwell Publication, Cambridge 1994; 453–460
   Google Scholar
• Kaplan E., Meier P. Nonparametric estimation from incomplete observations. American Statistical Association Journal 1958; 53: 457–481
   Web of Science ®Google Scholar
• Gehan E. A generalised Wilcoxon test for comparing arbitrarily single-censored samples. Biometrika 1965; 52: 203–223
   PubMed Web of Science ®Google Scholar
• Samoszuk M., Ramzi E. IgE, Reed-Sternberg cells, and eosinophilia in Hodgkin's disease. Leukemia and Lymphoma 1993; 9: 315–319
   PubMed Web of Science ®Google Scholar
• Samoszuk M., Sholly S., Epstein A. L. Eosinophil peroxidase is detectable with a monoclonal antibody in collagen bands of nodular sclerosis Hodgkin's disease. Laboratory Investigation 1987; 56: 394–400
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J., Jaffe E., Burd P., Kingma D., Setsuda J., Tosato G. Differential chemokine expression in tissues involved by Hodgkin's disease: Direct correlation of eotaxin expression and tissue eosinophilia. Blood 1999; 93: 2463–2470
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J., Tosato G., Jaffe E. The role of chemokines in Hodgkin's disease. Leukemia and Lymphoma 2000; 38: 363–371
   PubMed Web of Science ®Google Scholar
• van den Berg A., Visser L., Poppema S. High expression of the CC chemokine TARC in Reed-Stemberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. American Journal of Pathology 1999; 154: 1685–1691
   PubMed Web of Science ®Google Scholar
• Oudejans J., Jiwa N., Kummer J., Horstman A., Vos W., Baak J., Kluin P., van der Valk P., Walboomers J., Meijer C. Analysis of major histocompatibility complex class I expression on Reed-Stemberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and-negative Hodgkin's disease. Blood 1996; 87: 3844–3851
   PubMed Web of Science ®Google Scholar
• Dukers D., Jaspars L., Vos W., Oudejans J., Hayes D., Cillessen S., Middeldorp J., Meijer C. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and-negative cases of Hodgkin's disease. Journal of Pathology 2000; 190: 143–149
   PubMed Web of Science ®Google Scholar
• Kanavaros P., Vlychou M., Stefanaki K., Rontogianni D., Gaulard P., Pantelidaki E., Zois M., Darivianaki K., Georgoulias V., Boulland M. L., Gorgoulis V., Kittas C. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease. Anticancer Research 1999; 19: 1209–1216
   PubMed Web of Science ®Google Scholar
• Oudejans J., Kummer J. A., Jiwa M., van der Valk P., Ossenkoppele G., Kluin P., Kluin-Nelemans J. C., Meijer C. Granzyme B expression in Reed-Stemberg cells of Hodgkin's disease. American Journal of Pathology 1996; 148: 233–240
   PubMed Web of Science ®Google Scholar
• Dukers D., Oudejans J., Jaspars E., Gras M., Vos W., Middeldorp J. M., Meijer C., Bloemena E. All infiltrating T-lymphocytes in Hodgkin's disease express immunohistochemically detectable T-cell receptor ζ-chains in situ. Histopathology 2000; 36: 544–550
   PubMed Web of Science ®Google Scholar